
|Articles|December 5, 2012
FDA updated Safety Communication: Ondansetron (Zofran) 32-mg, single IV dose pulled due to potential for serious cardiac risks
The 32-mg, single intravenous dose of the anti-nausea drug Zofran will no longer be marketed because of the potential for serious cardiac risk, according to an updated Safety Communication from FDA.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Executive Order Calls for Realignment of Childhood Vaccines
2
The Prodigious PBM Pivot: How Supply Chain Entities Will Move Forward After CAA 2026
3
Q&A: Pharmacists Can Address ADA Standards Across All Settings
4
Embedded Pharmacists Are Vital Yet Underutilized in Diabetes Care
5





























































